By: Helen Albert
The oversubscribed series A funding shows investor interest in immune and inflammatory disease therapies remains strong
Helen Albert is a Senior Editor at various esteemed publications, including Chemistry World and Genetic Engineering & Biotechnology News. She specializes in medicine and healthcare, with a focus on topics such as gene therapy, immunology, and mental health care, while also covering advancements in healthcare technology and diagnostics. Helen's work has been featured in notable outlets like Inside Precision Medicine and Environmental Health News, showcasing her commitment to informing readers about critical developments in the medical field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
Helen's coverage is predominantly focused on healthcare and pharmaceuticals, with an emphasis on scientific breakthroughs. Her articles frequently cite data, indicating a preference for evidence-based reporting.
Given the technical and research-oriented nature of her articles, Helen would likely be interested in sources who can provide expert insights into cutting-edge medical research or technological advancements within the healthcare and pharmaceutical sectors.
Articles featuring biotech movies suggest she could also be open to human-interest pieces related to the industry. However, it's essential that pitches align with her focus on scientific and evidence-based content.
This information evolves through artificial intelligence and human feedback. Improve this profile .